Biotest
Dreieich
About Biotest
Biotest is a specialist in innovative haematology, clinical immunology and intensive care medicine. Biotest develops, manufactures and markets plasma proteins and biotherapeutic drugs. Their value chain extends from pre-clinical and clinical development to worldwide marketing and distribution. Biotest manufactures immunoglobulins, clotting factors and albumins which derive from human blood plasma. Biotest also develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest currently employs more than 2,500 people worldwide. The most important raw material for their pharmaceuticals is human blood plasma, which they process into effective and highly purified drugs in one of their world leading fractionation facilities in Europe. These medications are used to treat life-threatening diseases such as blood coagulation disorders (haemophilia), severe infections and immune system disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1,001 – 5,000
- Estimated revenue: $500K – $1M
- Website: biotest.comde
- Phone: +49 6103 8014406
Social Profiles
Canonical: https://fsome.com/organization/biotest-170226 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.